Advertisement
Screener

ASTRAZENECA PLC (AZN) Form 6-K: Report of foreign private issuer, 2020, Page 2

2.4 / 5 stars · 19/40 Roast Me

Add as a preferred source on Google

ASTRAZENECA PLC Form 6-K: Report of foreign private issuer

Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.

  • 2020-03-30: Form 6-K; Period of report 2020-03-30; Description FARXIGA PHASE III DAPA-CKD TRIAL WILL BE STOPPED EARLY AFTER OVERWHELMING EFFICA; Document a0051i.htm.
  • 2020-03-30: Form 6-K; Period of report 2020-03-30; Description IMFINZI APPROVED IN THE US FOR EXTENSIVE-STAGE SMALL CELL LUNG CANCER; Document a0057i.htm.
  • 2020-03-26: Form 6-K; Period of report 2020-03-26; Description DIRECTOR/PDMR SHAREHOLDING; Document a6259h.htm.
  • 2020-03-26: Form 6-K; Period of report 2020-03-26; Description LOKELMA APPROVED IN JAPAN FOR THE TREATMENT OF HYPERKALAEMIA; Document a6835h.htm.
FiledFormPeriod of reportDescriptionDocument
2020-03-306-K2020-03-30FARXIGA PHASE III DAPA-CKD TRIAL WILL BE STOPPED EARLY AFTER OVERWHELMING EFFICAa0051i.htm
2020-03-306-K2020-03-30IMFINZI APPROVED IN THE US FOR EXTENSIVE-STAGE SMALL CELL LUNG CANCERa0057i.htm
2020-03-266-K2020-03-26DIRECTOR/PDMR SHAREHOLDINGa6259h.htm
2020-03-266-K2020-03-26LOKELMA APPROVED IN JAPAN FOR THE TREATMENT OF HYPERKALAEMIAa6835h.htm
2020-03-206-K2020-03-20DIRECTOR/PDMR SHAREHOLDINGa8885g.htm
2020-03-196-K2020-03-19LYNPARZA GRANTED ORPHAN DRUG DESIGNATION IN JAPAN FOR BRCA-MUTATED METASTATIC PAa7611g.htm
2020-03-176-K2020-03-17IMFINZI CONFIRMED A SUSTAINED OVERALL SURVIVAL BENEFIT IN FINAL ANALYSIS OF THE a4187g.htm
2020-03-126-K2020-03-12NOTICE OF AGMa8387f.htm
2020-03-126-K2020-03-12UPDATE ON PHASE III GY004 TRIAL FOR CEDIRANIB ADDED TO LYNPARZA IN PLATINUM-SENSa8946f.htm
2020-03-126-K2020-03-126-Ka20-12289_16k.htm
2020-03-106-K2020-03-10DIRECTOR/PDMR SHAREHOLDINGa5051f.htm
2020-03-066-K2020-03-06UPDATE ON PHASE III DANUBE TRIAL FOR IMFINZI AND TREMELIMUMAB IN UNRESECTABLE, Sa2583f.htm
2020-03-046-K2020-03-04FILING OF FORM 20-F WITH SECa9158e.htm
2020-03-036-K2020-03-03ANNUAL FINANCIAL REPORTa8488e.htm
2020-03-026-K2020-03-02TOTAL VOTING RIGHTSa7258e.htm
2020-03-026-K2020-03-02ASTRAZENECA COMPLETES DIVESTMENT AGREEMENT WITH ATNAHS PHARMA FOR ESTABLISHED HYa6422e.htm
2020-02-276-K2020-02-27DIRECTOR/PDMR SHAREHOLDINGa2449e.htm
2020-02-256-K2020-02-25ASTRAZENECA DIVESTS GLOBAL RIGHTS TO MOVANTIKa0212e.htm
2020-02-196-K2020-02-19DIRECTOR/PDMR SHAREHOLDINGa3832d.htm
2020-02-146-K2020-02-14AZN: FULL-YEAR AND Q4 2019 RESULTSa9843cnew.htm
2020-02-036-K2020-02-03TOTAL VOTING RIGHTSa7794b.htm
2020-01-276-K2020-01-27PHASE II DESTINY-GASTRIC01 TRIAL OF ENHERTU VERSUS CHEMOTHERAPY MET PRIMARY ENDPa9771a.htm
2020-01-276-K2020-01-27ASTRAZENECA TO RECOVER THE GLOBAL RIGHTS TO BRAZIKUMAB (MEDI2070) FROM ALLERGANa9769a.htm
2020-01-276-K2020-01-27BRILINTA MET PRIMARY ENDPOINT IN PHASE III THALES TRIAL IN STROKEa9349a.htm
2020-01-276-K2020-01-27ASTRAZENECA DIVESTS RIGHTS TO ESTABLISHED HYPERTENSION MEDICINESa9347a.htm
2020-01-216-K2020-01-20LYNPARZA REGULATORY SUBMISSION GRANTED PRIORITY REVIEW IN THE US FOR HRR-MUTATEDa2858a.htm
2020-01-216-K2020-01-20IMFINZI AND TREMELIMUMAB GRANTED ORPHAN DRUG DESIGNATION IN THE US FOR LIVER CANa2852a.htm
2020-01-136-K2020-01-13LYNPARZA REGULATORY SUBMISSION GRANTED PRIORITY REVIEW IN THE US FOR 1ST-LINE MAa5582z.htm
2020-01-136-K2020-01-13UPDATE ON PHASE III STRENGTH TRIAL FOR EPANOVA IN MIXED DYSLIPIDAEMIAa5579z.htm
2020-01-066-K2020-01-06LOKELMA APPROVED IN CHINA FOR THE TREATMENT OF ADULT PATIENTS WITH HYPERKALAEMIAa8104y.htm
2020-01-066-K2020-01-06FARXIGA GRANTED FDA PRIORITY REVIEW FOR PATIENTS WITH HEART FAILURE WITH REDUCEDa8107y.htm
2020-01-026-K2020-01-02TOTAL VOTING RIGHTSa5775y.htm
Advertisement